HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver Eyes Acquisitions Following Sally Spin-Off

This article was originally published in The Rose Sheet

Executive Summary

Alberto-Culver's consumer products division will make acquisitions a top priority following the spin-off of Sally Beauty Company, the firm stated during a June 19 call announcing the decision

You may also be interested in...



Shareholders Approve Spin-Off Of Alberto-Culver Distribution Business

Alberto-Culver is on track to become a $1.4 bil. consumer product business after shareholders approved the spin-off of its distribution businesses Sally Beauty Company and Beauty Systems Group Nov. 10

Shareholders Approve Spin-Off Of Alberto-Culver Distribution Business

Alberto-Culver is on track to become a $1.4 bil. consumer product business after shareholders approved the spin-off of its distribution businesses Sally Beauty Company and Beauty Systems Group Nov. 10

Finance In Brief

J&J Q3: U.S. consumer sales were $1.14 bil. in the third quarter, representing an increase of 5.9% over the prior-year period, Johnson & Johnson announces Oct. 17. Worldwide consumer sales were $2.46 bil., an increase of 10.1% over the prior year, boosted in part by the international growth of skin care products primarily reflecting the recent acquisition of French skin care marketer Groupe Vendome (1"The Rose Sheet" March 27, 2006, In Brief). The sales performance included a 2% positive impact from currency...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel